Coherus BioSciences (CHRS) Expected to Announce Earnings on Monday

Coherus BioSciences (NASDAQ:CHRS) is projected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share and revenue of $43.88 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Coherus BioSciences Stock Up 4.5 %

Shares of Coherus BioSciences stock opened at $1.04 on Friday. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $2.64. The stock has a market cap of $120.53 million, a price-to-earnings ratio of -13.00 and a beta of 0.92. The company’s fifty day moving average is $1.25 and its 200 day moving average is $1.19.

Wall Street Analysts Forecast Growth

CHRS has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Coherus BioSciences in a research report on Thursday, January 23rd. Robert W. Baird upped their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.38.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.